scholarly journals PNS185 Solutions to the Comparator Question in the Absence of Licensed Comparators? a Retrospective Analysis of Orphan Drug and GENE Therapy Reimbursement in EU5 Markets

2020 ◽  
Vol 23 ◽  
pp. S671-S672
Author(s):  
A. Mumford ◽  
B. English ◽  
L. Sopena ◽  
R. Munetsi
2016 ◽  
Vol 27 (11) ◽  
pp. 916-925 ◽  
Author(s):  
Daniel Gaudet ◽  
Erik S. Stroes ◽  
Julie Méthot ◽  
Diane Brisson ◽  
Karine Tremblay ◽  
...  

1998 ◽  
Vol 11 (1) ◽  
pp. 54-71
Author(s):  
Peggy Bush

Biotechnology has contributed to important advances in the healthcare field. Products include various hormones, enzymes, cytokines, vaccines, and monoclonal antibodies, with use in diverse therapeutic areas. The majority of approved biotechnology-derived therapeutic products are recombinant proteins. Many have orphan drug status and, therefore, are used in relatively small patient populations. Newer generation biotechnology products are likely to include small molecules, gene therapy products, and increased numbers of vaccines and monoclonal antibody products. Biotechnology provides the means to develop diverse, innovative, and effective approaches to the prevention, treatment, and cure of human disease.


Author(s):  
Julie L. Wambaugh ◽  
Lydia Kallhoff ◽  
Christina Nessler

Purpose This study was designed to examine the association of dosage and effects of Sound Production Treatment (SPT) for acquired apraxia of speech. Method Treatment logs and probe data from 20 speakers with apraxia of speech and aphasia were submitted to a retrospective analysis. The number of treatment sessions and teaching episodes was examined relative to (a) change in articulation accuracy above baseline performance, (b) mastery of production, and (c) maintenance. The impact of practice schedule (SPT-Blocked vs. SPT-Random) was also examined. Results The average number of treatment sessions conducted prior to change was 5.4 for SPT-Blocked and 3.9 for SPT-Random. The mean number of teaching episodes preceding change was 334 for SPT-Blocked and 179 for SPT-Random. Mastery occurred within an average of 13.7 sessions (1,252 teaching episodes) and 12.4 sessions (1,082 teaching episodes) for SPT-Blocked and SPT-Random, respectively. Comparisons of dosage metric values across practice schedules did not reveal substantial differences. Significant negative correlations were found between follow-up probe performance and the dosage metrics. Conclusions Only a few treatment sessions were needed to achieve initial positive changes in articulation, with mastery occurring within 12–14 sessions for the majority of participants. Earlier occurrence of change or mastery was associated with better follow-up performance. Supplemental Material https://doi.org/10.23641/asha.12592190


2001 ◽  
Vol 120 (5) ◽  
pp. A349-A349
Author(s):  
J TSENG ◽  
F FARNEBO ◽  
O KISKER ◽  
C BECKER ◽  
C KUO ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document